Revisión de las reacciones de hipersensibilidad a antineoplásicos

Cortijo-Cascajares, Susana; Jiménez-Cerezo, M.J.; Tejada, Alberto Herreros de

doi:10.1016/j.farma.2011.02.004

Cited by 11 publications

(8 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, hypersensitivity reactions occur in up to 25% of the patients and 10% of those may experience life-threatening anaphylactic reactions (Cortijo-Cascajares et al, 2012). Studies on the pharmacogenetics of asparaginase in ALL are in their early stages.…”

Section: L-asparaginasementioning

confidence: 99%

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia

Gervasini¹,

Vagace²

2012

Front. Gene.

View full text Add to dashboard Cite

The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity. At the present time, the cornerstone of therapy for ALL is still formed by a reduced number of drugs with a highly toxic profile. In recent years, a number of genetic polymorphisms have been identified that can play a significant role in modifying the pharmacokinetics and pharmacodynamics of these drugs. The best example is that of the TPMT gene, whose genotyping is being incorporated to clinical practice in order to individualize doses of mercaptopurine. However, there are additional genes that are relevant for the metabolism, activity, and/or transport of other chemotherapy drugs that are widely use in ALL, such as methotrexate, cyclophosphamide, vincristine, L-asparaginase, etoposide, cytarabine, or cytotoxic antibiotics. These genes can also be affected by genetic alterations that could therefore have clinical consequences. In this review we will discuss recent data on this field, with special focus on those polymorphisms that could be used in clinical practice to tailor chemotherapy for ALL in order to reduce the occurrence of serious adverse effects.

show abstract

Section: L-asparaginasementioning

confidence: 99%

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia

Gervasini¹,

Vagace²

2012

Front. Gene.

View full text Add to dashboard Cite

show abstract

“…ALL is a blood and bone marrow‐related cancer whose prevalence is higher in childhood . Nowadays, ASNase based drugs are available in different preparations/formulations as described in Table …”

Section: Introductionmentioning

confidence: 99%

“…9,10 Nowadays, ASNase based drugs are available in different preparations/formulations as described in Table 1. [11][12][13][14][15][16] . However, there are some factors limiting its use as a chemotherapeutic agent, namely (i) the daily dose demand (10-200 IU.kg 21 per day), for different periods of time, which may last for 21 days, and (ii) the toxic side effects that can occur during therapy, i.e., hyperglycemia, decreased serum albumin, lipoproteins and fibrinogen, increased liver fat, some mild brain dysfunctions, 6,11,[17][18][19][20] and (iii) the development of hypersensitivity to treatment.…”

Section: Introductionmentioning

confidence: 99%

Heterologous expression and purification of active L‐asparaginase I of Saccharomyces cerevisiae in Escherichia coli host

Santos

Costa

Molino

et al. 2016

Biotechnology Progress

View full text Add to dashboard Cite

l-asparaginase (ASNase) is a biopharmaceutical widely used to treat child leukemia. However, it presents some side effects, and in order to provide an alternative biopharmaceutical, in this work, the genes encoding ASNase from Saccharomyces cerevisiae (Sc_ASNaseI and Sc_ASNaseII) were cloned in the prokaryotic expression system Escherichia coli. In the 93 different expression conditions tested, the Sc_ASNaseII protein was always obtained as an insoluble and inactive form. However, the Sc_ASNaseI (His) -tagged recombinant protein was produced in large amounts in the soluble fraction of the protein extract. Affinity chromatography was performed on a Fast Protein Liquid Chromatography (FPLC) system using Ni -charged, HiTrap Immobilized Metal ion Affinity Chromatography (IMAC) FF in order to purify active Sc_ASNaseI recombinant protein. The results suggest that the strategy for the expression and purification of this potential new biopharmaceutical protein with lower side effects was efficient since high amounts of soluble Sc_ASNaseI with high specific activity (110.1 ± 0.3 IU mg ) were obtained. In addition, the use of FPLC-IMAC proved to be an efficient tool in the purification of this enzyme, since a good recovery (40.50 ± 0.01%) was achieved with a purification factor of 17-fold. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:416-424, 2017.

show abstract

“…Etoposide is an essential component of chemotherapy in patients with rare gynecological malignancies such as germ cell tumors and gestational trophoblastic disease. It can be applied intravenously or orally in capsule form [1]. Etoposide is generally well tolerated.…”

Section: Introductionmentioning

confidence: 99%

Hypersensitivity to Etoposide in Case of Metastatic Gestational Choriocarcinoma

Lazović¹,

Milenkovic²,

Delić³

et al. 2013

Case Rep Oncol

View full text Add to dashboard Cite

Etoposide is commonly used in the treatment of a variety of neoplasms. Hypersensitivity reactions to etoposide are infrequently reported and include hypotension, hypertension, flushing, diaphoresis, chest discomfort, dyspnea, bronchospasm and loss of consciousness. We report the case of a 39-year-old woman who experienced acute bronchospasm, tachycardia, hypoxia and hypotension. The symptoms resolved within an hour after administration of intravenous fluids, methylprednisolone, diphenhydramine and oxygen. Subsequently, the patient was given etoposide phosphate without incident.

show abstract

Revisión de las reacciones de hipersensibilidad a antineoplásicos

Cited by 11 publications

References 99 publications

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia

Heterologous expression and purification of active L‐asparaginase I of Saccharomyces cerevisiae in Escherichia coli host

Hypersensitivity to Etoposide in Case of Metastatic Gestational Choriocarcinoma

Contact Info

Product

Resources

About